Company intelligence / Profile preview

Lunan Hope Pharmaceutical

Ownership: Private
Employees: ~9000
Development stage: Commercial

Overview

Lunan Hope Pharmaceutical, as part of Lunan Pharmaceutical Group, has multiple commercially approved drugs in China across small molecules, biosimilars, traditional Chinese medicine, and biologics. Select pipeline programs include novel bispecific antibodies (e.g., LNF1904) in Phase 1 for lymphoma and co-development of antibody-drug conjugates targeting oncology. Many products are approved and marketed in China and some have global filings.

Therapeutic areas: PsychiatryImmunologyGastroenterologyPulmonologyInfectious DiseasesOncologyCardiovascularHematologyEndocrinology
Modalities: Small moleculeMonoclonal antibodyBispecific T-cell Engager (BiTE)Herbal medicineBiosimilar
Industry: Pharma

Partnerships

Adcoris Biopharma (antibody-drug conjugate development)

Beyond the preview

Go deeper on Lunan Hope Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lunan Hope Pharmaceutical.

Explore the full profile